The Sunday evidence signal
Ovarian signals lengthen. The next tests stay hard.
Genmab reports a 109-patient antibody-drug conjugate cohort while Agenus follows a small immunotherapy cohort to three years.
JobReports original SVG editorial illustration
2
verified developments
5
public employer boards refreshed
5
current openings curated
24h
news window to 10:30 AM ET
Editorial counts only. The job shortlist comes from five named public employer boards and is not a national inventory or market-wide hiring measure.
Ovarian cancer / Phase 1/2
Genmab reports response and durability data for Rina-S
Genmab said rinatabart sesutecan produced a confirmed objective response rate of 45.9% among 109 patients in Part C of the open-label RAINFOL-01 trial. The investigational antibody-drug conjugate recorded five complete responses, a median response duration of 12.1 months and median progression-free survival of 9.5 months.
The cohort included heavily pretreated patients with platinum-resistant ovarian, primary peritoneal or fallopian-tube cancer. Serious adverse events were reported in roughly one-third of participants, while 5.5% discontinued treatment because of treatment-emergent adverse events.
Why it matters
The readout gives Genmab a larger clinical evidence set as four Phase 3 Rina-S studies advance. It remains a single-arm Phase 1/2 cohort without a randomized comparator; Rina-S is investigational, and the release did not announce hiring.
Ovarian cancer / Phase 1b follow-up
Agenus follows BOT+BAL survival to three years
Agenus reported an estimated three-year overall survival rate of 48% among 35 efficacy-evaluable patients in the recurrent ovarian-cancer cohort of C-800-01. The estimate was unchanged from year two; median overall survival was 14.8 months and the objective response rate was 23%.
This was a small, single-arm Phase 1b cohort with a December 2025 data cutoff, not a randomized comparison. The 35 patients had received a median of four prior treatment lines, and the company said no new safety signals or treatment-related deaths appeared in the update. Botensilimab and balstilimab are not FDA approved.
Why it matters
Longer follow-up helps test whether an early response signal persists in heavily pretreated disease. It does not establish comparative benefit, and the announcement did not connect the result to a staffing plan.
Public-board shortlist
Five current roles worth a closer look
These openings were visibly checked on their employers' application pages before publication. They are independent of the news above; no direct connection between an announcement and a listed role has been established.
Associate Director, Scientific Communications
Waltham, Massachusetts
Associate Director, Regulatory Affairs
Remote
Director / Senior Director of Statistical Programming
Waltham, Massachusetts
Sr Bioinformatics Scientist
South San Francisco, California
Senior Research Associate, Oligonucleotide Chemistry
Somerville, Massachusetts
The takeaway
Longer follow-up sharpens the question; it does not settle it.
Both releases add clinical evidence in difficult-to-treat ovarian cancer, but both remain non-randomized and neither supports a broad hiring conclusion. The five openings instead offer a separate, current view of scientific communications, regulation, statistics, computing and laboratory work across a deliberately bounded public-board sample.
Explore previous briefings